Table 1.

The demographic and clinical features in patients with systemic sclerosis.

CharacteristicBaseline
Age at diagnosis*48±13.7
Female sex, n (%)131 (89.7)
Duration of follow-up, months**71 (6-228)
Disease subtype, n (%)
Diffuse / Limited66 (45.2) / 80 (54.8)
Autoantibodies, n (%)
Anti-Scl70 antibody50/143 (35.0)
Anti-Centromere antibody62/143 (43.4)
Immunsuppresive medication, ever, n (%)
Hydroxychloroquine91/143 (63.6)
Mycophenolate mofetil18/145 (12.4)
Azathioprine47/145 (32.4)
Cyclophosphamide24/145 (16.6)
Glucocorticoid80/140 (57.1)
Others, n (%)
ILD68/130 (52.3)
Pericardial effusion, ever26/133 (19.5)
Esophageal dilation (detected by CT)51/128 (39.8)
sPAP ≥35mmHg, ever (measured by ECHO)46/142 (32.4)
  • *Parameter presented as mean±SD

  • **Parameter presented as median (min-max)

  • CT, computed tomography; ECHO, echocardiogram; ILD, interstitial lung disease; sPAP, systolic pulmonary artery pressure